Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Forge Biologics

Forge Biologics Announces AAV Development and cGMP Manufacturing Relationship with Fractyl Health to Advance Their Gene Therapy Platform for Patients with Metabolic Diseases
From Forge Biologics
Via Business Wire
Forge Biologics Announces Eight Presentations at the American Society of Gene and Cell Therapy (ASGCT) 28th Annual Meeting
From Forge Biologics
Via Business Wire
Forge Biologics Announces the FUEL™ AAV Manufacturing Platform to Provide Developers with a More Efficient Solution for Gene Therapy Production
From Forge Biologics
Via Business Wire
Forge Biologics Announces Planned CEO Succession
From Forge Biologics
Via Business Wire
Muscular Dystrophy Association and Forge Biologics Announce AAV Development and Manufacturing Partnership
From Forge Biologics
Via Business Wire
Forge Biologics Announces Nine Presentations at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting
From Forge Biologics
Via Business Wire
Forge Biologics’ Novel AAV Gene Therapy FBX-101 for Patients with Krabbe Disease is Granted UK’s Innovation Passport Designation
From Forge Biologics
Via Business Wire
Forge Biologics Announces Positive FBX-101 Clinical Trial Update in Patients with Krabbe Disease Identified by Newborn Screening Ahead of RUSP Vote
From Forge Biologics
Via Business Wire
Forge Biologics Announces Publication in Human Gene Therapy on a Novel Finding That Changes a Fundamental Understanding of AAV Production
From Forge Biologics
Via Business Wire
Ajinomoto Co., Inc. to Acquire Forge Biologics for $620 Million1
From Forge Biologics
Via Business Wire
Forge Biologics Selected as an AAV Manufacturing Partner for California Institute for Regenerative Medicine to Help Accelerate Gene Therapy Programs
From Forge Biologics
Via Business Wire
Forge Biologics to Participate in Multiple September Investor Conferences
From Forge Biologics
Via Business Wire
New Hope Research Foundation and Forge Biologics Announce cGMP Manufacturing Partnership to Accelerate Gene Therapy for Patients with Tay-Sachs Disease
From Forge Biologics
Via Business Wire
Forge Biologics Joins Bespoke Gene Therapy Consortium (BGTC) as Partner to Accelerate the Development and Manufacturing of AAV Gene Therapies for Patients with Rare Diseases
From Forge Biologics
Via Business Wire
Forge Biologics Announces Eight Presentations at the Upcoming 2023 Meeting of the American Society of Gene and Cell Therapy (ASGCT)
From Forge Biologics
Via Business Wire
Forge Biologics and Labcorp Announce Strategic AAV Gene Therapy Development and Manufacturing Collaboration
From Forge Biologics
Via Business Wire
Forge Biologics Receives Qualified Person (QP) Declaration to Manufacture AAV Gene Therapies to Support European Clinical Programs
From Forge Biologics
Via Business Wire
Forge Biologics Reports Positive FBX-101 Clinical Updates for Patients with Krabbe Disease at WORLDSymposium
From Forge Biologics
Via Business Wire
Forge Biologics Deepens Genetic Medicine CDMO Capabilities with Leadership Team Expansion Across cGMP Manufacturing, Analytical Development, and Client Development
From Forge Biologics
Via Business Wire
Forge Biologics Receives Priority Medicines (PRIME) Designation from the European Medicines Agency (EMA) for Novel Gene Therapy FBX-101 for the Treatment of Patients with Krabbe Disease
From Forge Biologics
Via Business Wire
Forge Biologics and Oculogenex Announce AAV Contract Development and Manufacturing Partnership
From Forge Biologics
Via Business Wire
Forge Biologics, a Leading Manufacturer of Genetic Medicines, to Present at 41st Annual J.P. Morgan Healthcare Conference
From Forge Biologics
Via Business Wire
Eikonoklastes Therapeutics and Forge Biologics Announce Viral Vector Contract Development and AAV Manufacturing Partnership
From Forge Biologics
Via Business Wire
Forge Biologics Announces Updated Positive Clinical Data in RESKUE, a Novel Phase 1/2 Gene Therapy Trial for Patients with Krabbe Disease
From Forge Biologics
Via Business Wire
Ray Therapeutics and Forge Biologics Expand Their Viral Vector cGMP Partnership to Encompass Plasmid DNA Manufacturing
From Forge Biologics
Via Business Wire
Forge Biologics to Present and Participate at Upcoming Investor Conferences
From Forge Biologics
Via Business Wire
Forge Biologics Fuels Gene Therapy Manufacturing Engine with Launch of Plasmid DNA Manufacturing Services to Support AAV Clients
From Forge Biologics
Via Business Wire
Forge Biologics Announces $90 Million Series C Financing to Expand Client Offerings and Add Services to Enhance End-to-End Gene Therapy Manufacturing Platforms
From Forge Biologics
Via Business Wire
Forge Biologics to Present at Morgan Stanley’s 20th Annual Global Healthcare Conference
From Forge Biologics
Via Business Wire
Forge Biologics Reports Positive Clinical Data on Brain Development and Motor Function from the RESKUE Novel Phase 1/2 Gene Therapy Trial in Patients with Krabbe Disease at the SSIEM Annual Symposium
From Forge Biologics
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.